Drug
Basiliximab clinical trials
Also written Simulect and SDZ-CHI-621.
- studies test it
- 45
- open now
- 4
- in phase 3
- 8
- first study started
- 2002
Keep track of what changes. Save the Basiliximab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
45 studies that test it; most in 2006 (4)
| Year | Studies |
|---|---|
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 4 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 4 |
| 2013 | 2 |
| 2015 | 2 |
| 2017 | 3 |
| 2018 | 3 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 19
- Phase 3
- 8
- Phase 4
- 14
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 31
Novartis (6) · Cerimon Pharmaceuticals (3) · City of Hope Medical Center (2) · University of Chicago (2) · Astellas Pharma Inc (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · University Hospital Freiburg (2) · University Hospital, Toulouse (1)
Often tested with
Tested in the same studies.
Tacrolimus (8) · Mycophenolic Acid (7) · Thymoglobulin (4) · Everolimus (3) · Fludarabine (2) · Methylprednisolone (2) · Prednisolone (2) · Etanercept (2)
Studies
Open first, then newest update. How each study uses Basiliximab is read from its arms, and is right about nine times in ten.
Testing it · 45
- Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin LymphomaRecruitingPhase 2City of Hope Medical CenterNCT04871607Written as Basiliximab
- Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic DiseasesNot yet recruitingPhase 2Anhui Provincial HospitalNCT06480630Written as Basiliximab
- Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal InvolvementRecruitingPhase 4The First Affiliated Hospital of Soochow UniversityNCT06066840Written as Basiliximab
- Standard Induction With Basiliximab Versus No-Induction in Low Immunological Risk Kidney Transplant RecipientsRecruitingPhase 4King Faisal Specialist Hospital & Research CenterNCT04404127Written as Basiliximab 20 milligram [Simulect]
- 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic SyndromeActive, not recruitingPhase 1City of Hope Medical CenterNCT05139004Written as Basiliximab
- Simulect Versus ATG in Sensitized Renal Transplant PatientCompletedPhase 4University Hospital, ToulouseNCT02377193Written as Simulect
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant RecipientsCompletedPhase 2Novartis PharmaceuticalsNCT03663335Written as Induction therapy: basiliximab
- Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver TransplantCompletedPhase 4Fady M Kaldas, M.D., F.A.C.S.NCT04104438Written as Basiliximab 20 MG
- Stem Cell Transplantation for Patients With Multiple MyelomaCompletedPhase 1University of ChicagoNCT01526096Written as Basiliximab
- Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia MajorCompletedPhase 4Zhongming ZhangNCT02342145Written as Basiliximab,
- A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney RejectionCompletedPhase 4Astellas Pharma IncNCT00717470Written as Simulect
- Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver TransplantationCompletedPhase 3Astellas Pharma IncNCT01011205Written as Basiliximab
- Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft OutcomeCompletedPhase 4Chong Kun Dang PharmaceuticalNCT03794492Written as Basiliximab
- Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal TransplantCompletedPhase 2Massachusetts General HospitalNCT02464878Written as Basiliximab
- DC Migration Study for Newly-Diagnosed GBMCompletedPhase 2Mustafa Khasraw, MBChB, MD, FRCP, FRACPNCT02366728Written as Basiliximab
- Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver TransplantationCompletedPhase 4University of California, Los AngelesNCT02123108Written as Basiliximab
- Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult PatientsStatus unknownPhase 2Fort Worth Clinical Sciences Working GroupNCT05013034Written as Basiliximab Injection
- Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused LymphopeniaCompletedPhase 1Gary Archer Ph.D.NCT00626483Written as basiliximab
- Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCLStatus unknownPhase 2Beijing Tongren HospitalNCT04337593Written as Basiliximab
- Islet Transplantation in Type 1 DiabetesCompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT00434811Written as Basiliximab
See all 45 studies that test Basiliximab →
Given in every arm · 26 — Basiliximab is usual care beside what is tested
- Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin LymphomaCompletedPhase 1City of Hope Medical CenterNCT01476839Written as basiliximab
- Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive RegimenTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01856257Written as basiliximab
- Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal TransplantationTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01436305Written as Basiliximab
- A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant RecipientsCompletedPhase 2Astellas Pharma Global Development, Inc.NCT01780844Written as Basiliximab
- Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant RecipientsCompletedPhase 2Astellas Pharma Global Development, Inc.NCT02921789Written as Basiliximab
- Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal AllograftsCompletedPhase 3Astellas Pharma IncNCT00933231Written as Simulect
- A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without SteroidsCompletedPhase 4Astellas Pharma IncNCT01304836Written as Simulect
- Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCTCompletedPhase 3Peking University People's HospitalNCT04738981Written as Anti-CD25 mAb
- Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet TransplantationCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00789308Written as Simulect® (Basiliximab) - at 2nd or 3rd transplant
- A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal TransplantationWithdrawnPhase 2/3Genentech, Inc.NCT00729768Written as basiliximab
- 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant PatientsCompletedPhase 3Novartis PharmaceuticalsNCT01843348Written as Simulect
- Steroid Withdrawal in Pediatric Kidney Transplant RecipientsTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00023244Written as Basiliximab
- A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant RecipientsCompletedPhase 3Novartis PharmaceuticalsNCT01625377Written as Basiliximab
- LEA29Y (Belatacept) Emory Edmonton ProtocolCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00468403Written as Basiliximab
- Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant PatientsCompletedPhase 4Associação Médico Espírita de BotucatuNCT02683291Written as Basiliximab
- Preservation of Renal Function in Liver Transplant Recipients With Certican TherapyCompletedPhase 3Novartis PharmaceuticalsNCT00378014Written as basiliximab
- Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant RecipientsCompletedPhase 4Novartis PharmaceuticalsNCT00965094Written as Basiliximab
- Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant RecipientsCompletedPhase 4Novartis PharmaceuticalsNCT00634920Written as Basiliximab
- Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)CompletedPhase 2Novartis PharmaceuticalsNCT01596062Written as Simulect®
- Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney TransplantWithdrawnPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00790439Written as Basiliximab
Showing 20 of 26.
As the comparator · 11 — what is tested is compared with Basiliximab
- Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDiesRecruitingPhase 3University Hospital, ToursNCT05385432Written as Basiliximab
- Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive TreatmentTerminatedPhase 4Centre Hospitalier Universitaire de Saint EtienneNCT02523768Written as Simulect
- Campath, Calcineurin Inhibitor Reduction and Chronic Allograft NephropathyCompletedPhase 2/3University of OxfordNCT01120028Written as Basiliximab
- Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant PatientsCompletedPhase 4Coordinación de Investigación en Salud, MexicoNCT03006419Written as Basiliximab
- Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose RegimenCompletedPhase 3Novartis PharmaceuticalsNCT00514514Written as Simulect®
- A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant RecipientsCompletedPhase 2Astellas Pharma IncNCT00543569Written as basiliximab
- Effect of SVF Derived MSC in DCD Renal TransplantationStatus unknownPhase 1/2Fuzhou General HospitalNCT02492490Written as Basiliximab
- The Usefulness of Tacrolimus Without Basiliximab in Well Matched Living Renal Transplantation in KoreaStatus unknownNot applicableAsan Medical CenterNCT02459977Written as Basiliximab
- An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.CompletedPhase 2Genzyme, a Sanofi CompanyNCT00235300Written as Simulect (basliximab)
- Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant RecipientsCompletedPhase 4Astellas Pharma IncNCT00113269Written as basiliximab
- Thymoglobulin Induction in Kidney Transplant RecipientsStatus unknownPhase 3University of OxfordNCT01239563Written as Basiliximab
Codes
What other systems call Basiliximab · ClinicalTrials.gg INT006748
- MeSH (NLM) D000077552BasiliximabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 9927MT646MBASILIXIMABConfirmed FDA, NLM, Wikidata
- RxNorm 196102Confirmed FDA, Wikidata
- Wikidata Q418702basiliximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C52186BasiliximabOne source FDA
- DrugBank DB00074One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077552 | Basiliximab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 9927MT646M | BASILIXIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 196102 | — | Confirmed FDA, Wikidata |
| Wikidata | Q418702 | basiliximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C52186 | Basiliximab | One source FDA |
| DrugBank | DB00074 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.